Ascendis Pharma grants Novo Nordisk exclusive global license for TransCon tech in metabolic and cardiovascular disease products. Ascendis eligible for $285 million upfront, milestone, and sales ...

Its availability has been limited anyway, offered only through a Takeda special use ... Ascendis’s submission, citing in part concerns about dosing variability from the drug/device combination ...

Thirteen-year-old Ascendis produces brands such as Vitaforce supplements, Nimue skin products and Solal supplements ... This week the group said that Acorn Agri & Food had made an offer for its animal ...

Compassionate use enables treating physicians ... and initiate enrollment by contacting ascendis.medical@mytomorrows.com. In Germany, access to medicinal products that have not yet received ...